Syncom Formulations Announces Resignation of Whole-Time Director Kedarmal Bankda
Mr. Kedarmal Shankarlal Bankda has resigned as Whole-Time Director of Syncom Formulations (India) Limited. His resignation is effective August 11, 2026. The company received the resignation letter on August 8, 2026.
The resignation of a single Whole-Time Director, without additional information on the reasons or the director's specific impact on the company's operations, is unlikely to have a significant short-term impact on the company's stock or business.
The resignation of a director is a routine corporate event and does not inherently carry a positive or negative financial implication without further context.
Syncom Formulations (India) Limited has announced the resignation of Mr. Kedarmal Shankarlal Bankda (DIN: 00023050) from his position as Whole-Time Director. The resignation was tendered via a letter and was received by the company on August 8, 2026, at 10:35 AM. The cessation of his role as Whole-Time Director is effective from August 11, 2026.
The company has provided the requisite disclosure as per Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and the relevant SEBI Master Circular. The disclosure includes the reason for the change, which is the resignation of Mr. Bankda, and the effective date of cessation. Information regarding his brief profile and any relationship between directors was stated as not applicable.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.